Table 2. Comparison between DNA methylation status and clinical information.
| Demethylation status of MUC1 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| neoplastic region | non-neoplastic region | ||||||||||
| n (%) | mean±SD | p value | n (%) | mean±SD | p value | ||||||
| Sex | M | 53 (51.5%) | 54.71 | ± | 15.1 | 0.034 | 88 (53.7%) | 60.42 | ± | 15.0 | 0.050* |
| F | 50 (48.5%) | 47.75 | ± | 18.1 | 76 (46.3%) | 54.92 | ± | 20.0 | |||
| Age | >60 | 75 (72.8%) | 49.67 | ± | 15.5 | 0.104 | 115 (69.7%) | 57.07 | ± | 18.1 | 0.354 |
| <60 | 28 (27.2%) | 55.67 | ± | 19.8 | 50 (30.3%) | 59.82 | ± | 16.4 | |||
| TNM | |||||||||||
| T | T1 & T2 | 7 (8.5%) | 48.02 | ± | 26.6 | 0.703 | 36 (27.1%) | 62.21 | ± | 13.2 | 0.052* |
| T3 & T4 | 75 (91.5%) | 50.75 | ± | 17.3 | 97 (72.9%) | 55.58 | ± | 18.7 | |||
| N | negative | 47 (50.0%) | 51.82 | ± | 17.2 | 0.619 | 88 (56.8%) | 60.27 | ± | 16.3 | 0.061 |
| positive | 47 (50.0%) | 50.05 | ± | 17.5 | 67 (43.2%) | 55.02 | ± | 18.6 | |||
| M | negative | 87 (93.5%) | 52.77 | ± | 15.6 | 0.002 | 149 (96.8%) | 58.40 | ± | 17.5 | 0.172 |
| positive | 6 (6.5%) | 31.20 | ± | 19.6 | 5 (3.2%) | 47.49 | ± | 14.7 | |||
| Stage | IA & IB | 6 (7.3%) | 45.79 | ± | 28.4 | 0.021** | 29 (21.8%) | 62.28 | ± | 13.2 | 0.183** |
| IIA & IIB | 67 (81.7%) | 52.85 | ± | 16.2 | 96 (72.2%) | 56.35 | ± | 18.8 | |||
| III & IV | 9 (11.0%) | 35.86 | ± | 18.0 | 8 (6.0%) | 51.76 | ± | 14.0 | |||
| Historogy | por | 5 (9.6%) | 50.67 | ± | 11.2 | 0.911 | 7 (7.7%) | 59.53 | ± | 22.8 | 0.816 |
| tub | 47 (90.4%) | 51.45 | ± | 16.5 | 84 (92.3%) | 58.05 | ± | 16.6 | |||
| Demethylation status of MUC4 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| neoplastic region | non-neoplastic region | ||||||||||
| n (%) | mean±SD | p value | n (%) | mean±SD | p value | ||||||
| Sex | M | 53 (51.5%) | 72.32 | ± | 17.1 | 0.628 | 88 (53.7%) | 70.31 | ± | 13.9 | 0.089* |
| F | 50 (48.5%) | 70.61 | ± | 19.0 | 76 (46.3%) | 66.69 | ± | 13.2 | |||
| Age | >60 | 75 (72.8%) | 70.96 | ± | 17.5 | 0.626 | 115 (69.7%) | 68.53 | ± | 13.5 | 0.887 |
| <60 | 28 (27.2%) | 72.88 | ± | 19.5 | 50 (30.3%) | 68.85 | ± | 14.1 | |||
| TNM | |||||||||||
| T | T1 & T2 | 7 (8.5%) | 60.18 | ± | 26.1 | 0.08 | 36 (27.1%) | 66.34 | ± | 10.6 | 0.265* |
| T3 & T4 | 75 (91.5%) | 72.62 | ± | 16.9 | 97 (72.9%) | 69.29 | ± | 14.4 | |||
| N | negative | 47 (50.0%) | 68.81 | ± | 19.6 | 0.313 | 88 (56.8%) | 66.75 | ± | 13.7 | 0.234 |
| positive | 47 (50.0%) | 72.57 | ± | 16.7 | 67 (43.2%) | 69.33 | ± | 13.0 | |||
| M | negative | 87 (93.5%) | 71.55 | ± | 17.7 | 0.077 | 149 (96.8%) | 68.13 | ± | 13.0 | 0.045 |
| positive | 6 (6.5%) | 57.92 | ± | 23.1 | 5 (3.2%) | 55.96 | ± | 19.8 | |||
| Stage | IA & IB | 6 (7.3%) | 57.61 | ± | 27.6 | 0.028** | 29 (21.8%) | 66.36 | ± | 11.1 | 0.369** |
| IIA & IIB | 67 (81.7%) | 73.96 | ± | 16.0 | 96 (72.2%) | 69.48 | ± | 13.5 | |||
| III & IV | 9 (11.0%) | 62.70 | ± | 20.6 | 8 (6.0%) | 64.31 | ± | 20.5 | |||
| Historogy | por | 5 (9.6%) | 60.93 | ± | 17.8 | 0.109 | 7 (7.7%) | 59.70 | ± | 9.9 | 0.034 |
| tub | 47 (90.4%) | 73.91 | ± | 18.5 | 84 (92.3%) | 70.42 | ± | 13.7 | |||
p value is calculated by equal variance t. test, Unequal variance t. test (*) or ANOVA test (**).